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Abstract
Introduction: Despite the known importance of somatostatin analogues (SSAs) in the treatment of acromegaly, patient satisfaction leading 
to preferences for specific SSAs have received little attention so far.
Material and methods: This open, prospective, observational, multicentre patient-reported outcome study included adult patients with 
acromegaly, who switched from another SSA to lanreotide Autogel (new and previous devices) at least two months prior to enrolment. 
The observation period was around 12 months. The primary outcome assessed was overall treatment satisfaction, measured using the 
five-point Likert scale. The secondary outcomes were: 1) treatment effectiveness, in terms of symptom control; 2) technical problems 
related to treatment administration, measured by the Visual Analog Scale (VAS); and 3) ease and safety of lanreotide Autogel delivery 
(new device vs. previous device). 
Results: Of the 102 patients who completed the study, 97 (95.1%) were “completely or rather satisfied” with lanreotide Autogel therapy, 
four (3.9%) were “neither satisfied nor dissatisfied”, and one (1%) was “rather dissatisfied”. Symptom control was reported as “excellent” 
or “good” by 88–89% of patients throughout the study. Patients reported fewer technical problems related to administration of lanreotide 
Autogel (final mean VAS: 5.3) compared to previous SSAs (mean VAS: 37.6). Of the 31 patients treated with lanreotide Autogel using the 
previous device followed by the new device, 64.5% reported the new device as improved. 
Conclusions: Lanreotide Autogel therapy resulted in greater patient satisfaction with overall acromegaly management, when compared to 
previous SSAs. The new lanreotide Autogel device was found to be easier to use than the previous one. (Endokrynol Pol 2016; 67 (6): 572–579)
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Streszczenie
Wstęp: Pomimo znanego znaczenia analogów somatostatyny (SSA) w leczeniu akromegalii, dotychczas nie poświęcono wiele uwagi 
zadowoleniu pacjenta i preferencjom dotyczącym poszczególnych SSA.
Materiał i metody: Było to otwarte, prospektywne, obserwacyjne, wieloośrodkowe badanie, oparte na samoocenie przez pacjenta wyni-
ków leczenia. Obejmowało dorosłych pacjentów z akromegalią, którzy zmienili inny SSA na lanreotyd Autogel (nowe i stare aplikatory), 
co najmniej 2 miesiące przed włączeniem do badania. Okres obserwacji wynosił około 12 miesięcy. 
Podstawowym ocenianym wynikiem była ogólna satysfakcja z leczenia, mierzona za pomocą 5-punktowej skali Likerta. Wyniki 
uzupełniające były następujące: 1) efektywność leczenia pod względem kontroli objawów; 2) problemy techniczne związane z podawa-
niem leku, mierzone za pomocą wizualnej skali analogowej (VAS); i 3) łatwość i bezpieczeństwo stosowania lanreotydu Autogel (nowe 
urządzenie vs. stare urządzenie).
Wyniki: Spośród 102 pacjentów, którzy ukończyli badanie, 97 (95,1%) było “w pełni lub raczej zadowolonych“ z terapii lanreotydem Autogel, 
czterech (3,9%) było ”ani zadowolonych, ani niezadowolonych“, a jeden był ”raczej niezadowolony“. Kontrola objawów była oceniona 
jako “doskonała“ lub ”dobra“ przez 88–89% pacjentów w całym badaniu. Pacjenci zgłaszali mniej problemów technicznych związanych 
z podawaniem lanreotydu Autogel (końcowa średnia VAS: 5,3) w porównaniu z poprzednimi SSA (średnia VAS: 37,6). Spośród 31 pacjentów 
leczonych lanreotydem Autogel korzystających ze starego urządzenia, a następnie z nowego, 64,5% oceniło nowe urządzenie jako lepsze.
Wnioski: Terapia lanreotydem Autogel skutkowała większym zadowoleniem pacjentów z ogólnego postępowania w akromegalii, 
w porównaniu z poprzednimi SSA. Nowe urządzenie do aplikowania lanreotydu Autogel okazało się łatwiejsze i bezpieczniejsze w użyciu 
niż poprzednie. (Endokrynol Pol 2016; 67 (6): 572–579)
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Introduction
Acromegaly is a chronic disease, caused by growth hor-
mone (GH) secreting pituitary adenoma, which in turn 
results in overproduction of insulin-like growth factor-1 
(IGF-1). It leads to typical clinical symptoms as well as 
metabolic and cardiovascular complications, and largely 
impaired quality of life (QoL) [1]. The mortality rates in 
patients with untreated or poorly controlled acromegaly 
are increased compared with the general population [2]. 
Thus, effective therapy is key to reversing biochemical 
abnormalities, ameliorating symptoms, and ultimately 
restoring patient well-being, normal personal and so-
cietal functioning, as well as increasing life expectancy.
Surgery is the first-line treatment of acromegaly 
and often is followed by pharmacological therapy and 
radiotherapy [3]. Transsphenoidal resection of a pitui-
tary tumour either removes or substantially decreases 
the size of the tumour, thus preventing intracranial 
complications [1]. When surgery cannot be performed 
or is unsuccessful, whether because of a non-fully re-
sectable tumour, clinical contraindications, or patient 
refusal, alternative therapies must be considered. One 
such pharmacological alternative is the somatostatin 
analogues (SSAs): long-term SSA treatment has been 
shown to be effective both in terms of hormonal nor-
malisation and tumour shrinkage [4, 5]. Nowadays, 
three SSAs (lanreotide, octreotide, and pasireotide) 
are available in Poland. All are effective in decreasing 
GH secretion and IGF-1 levels [6]; however, there have 
been no head-to-head studies. In a small, randomised 
crossover study, Andries et al. showed comparable ef-
fects of lanreotide and octreotide on biochemical control 
of acromegaly in some, but not all, patients. At the same 
time, the authors observed various response profiles in 
a proportion of their study population, leading them to 
the conclusion that a change from one drug to another 
maybe beneficial in patients displaying poor treatment 
response or side effects [7].
In light of the burden of long-term parenteral treat-
ment, patient treatment perception is critical, primarily 
for adherence to treatment and thus for achieving op-
timal treatment effects [8]. To accurately gauge patient 
preference, a survey of patient-reported outcomes is 
considered preferable, as it helps determine the ef-
ficacy of treatment and interpret clinical results from 
a patient’s perspective, and it supports the treating phy-
sician in making decisions about the patient’s therapy. 
Overall patient preference, especially in the case of 
chronic disorders, is a mandatory component of current 
models of shared doctor–patient decision making [9]. 
Despite the known importance of this aspect of patient 
treatment, very little has been published on this issue 
in terms of acromegaly [10–12].
Nevertheless, it should be noted that treatment pref-
erence is a notion specific to culture and the mentality 
of the societal setting, and one that is dependent on the 
health care system. Therefore, it is important that it is 
studied in a certain sociocultural context [13]. A better 
understanding of treatment preference specific for the 
Polish population of patients with acromegaly is of im-
portance in enhancing patient adherence to treatment 
and, in turn, patients’ health outcomes [14].
Our study aims at broadening our knowledge by 
assessing treatment preference in adult patients with 
acromegaly, who were being treated with lanreotide 
Autogel, after having switched from other SSAs.
Material and methods
The study presented herein was designed as an open, 
prospective, observational, non-interventional, multi-
centre, patient-reported outcome study. All local regu-
latory requirements applicable to non-interventional 
studies were fulfilled; approval by the Local Ethics 
Committee was sought and confirmed. This study 
followed the recommendations of the Declaration of 
Helsinki (2008), as well as relevant epidemiological 
guidelines [15–17].
Eligibility for participation in the study was assessed 
during routine outpatient visits. Adult patients with 
acromegaly were included to the study, if they were 
switched from octreotide to lanreotide as of January 1, 
2012, and treated with lanreotide Autogel (including 
a new type of device) for at least two months prior to 
enrolment in the study. The decision to prescribe lanreo-
tide Autogel was made prior to and independently from 
the decision to enrol patients to this study. Participants 
were notified of the details of the study by their treat-
ing physician, and provided written informed consent 
to participate in the study. To preserve transparency, 
investigators included consecutive subjects to achieve 
the recruitment target (targets per centre). The choice 
of centres was based on the ability to collect the data, 
motivation to participate in the study, and fulfilling the 
requirements of the protocol.
The observation period for each participant was 
approximately 12 months. Data were collected during 
four visits: one enrolment visit (V0) and three follow-up 
visits (V1, V2, and V3), each of which was held within 
four months of the previous visit. No additional assess-
ments or tests were required. Treatment monitoring, 
dose adjustment, and all other medical decisions were 
made at the discretion of the treating physician, and 
all assessments and procedures were conducted in ac-
cordance with routine medical practice at the study site. 
Therefore, participation in the study did not expose the 
subjects to additional risks or burdens. 
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The primary study objective was to assess patients’ 
satisfaction with, and thus indirectly preference for, 
lanreotide Autogel treatment compared with previous 
SSA. The secondary objective was to assess patients’ 
preference for a new lanreotide Autogel device (new 
pre-formulated preparation in a pre-filled syringe; 
1.2 mm needle for all doses, including a rigid needle cap, 
automatic needle guard to prevent needle-stick injuries, 
and a fully transparent delivery system) compared with 
the previous lanreotide Autogel device.
Several items were recorded at the enrolment visit: 
demographic details, relevant medical history, and prior 
treatment including surgery and medication. Data on 
previous use of SSAs, with a focus on SSA treatment 
regimen and reasons for the change in treatment, were 
collected. Information relating to the current medical 
therapy, in particular the use of lanreotide Autogel 
(dose, frequency, details of administration), was gath-
ered at each visit. 
The primary study endpoint was overall treat-
ment satisfaction with lanreotide Autogel assessed at 
the end of the study using the five-point Likert scale 
(from completely satisfied to completely dissatisfied). 
The secondary endpoints were: 1) lanreotide Autogel 
treatment effectiveness in terms of acromegaly symp-
tom control (five-point Likert scale: excellent, good, 
acceptable, poor, and very poor); 2) technical problems 
related to administration of lanreotide Autogel, as meas-
ured by the Visual Analogue Scale (VAS), anchored as 
“no technical problems” — coded as 0, and “technical 
problems” — coded as 100); and, 3) the ease of inject-
ing lanreotide Autogel from a new type of device and 
the safety of the pre-filled syringe. Technical problems 
related to drug administration and the ease of injecting 
lanreotide Autogel were evaluated either by patient/ 
/partner or doctor/nurse, depending on who adminis-
tered the drug.
Statistical analysis was performed using Statistical 
Analysis System (SAS) version 9.2. Data are presented 
as descriptive summary statistics (n, mean, standard 
deviation [SD]) or frequency counts (percentage [%]).
Results
Patient characteristics
Of 114 patients screened, 113 (aged 18–80 years; 40.7% 
men) were enrolled in the study. Over the 12-month 
follow-up, 11 patients withdrew from the study (one 
due to adverse event, one due to lack of efficacy, and 
nine were lost to follow-up) (Fig. 1). The mean (SD) du-
ration of study participation was 10.3 (2.51) months, and 
the mean (SD) duration of treatment with lanreotide 
Autogel was 15.4 (9.59) months. The demographics of 
the enrolled population are summarised in Table I. In 
the studied population, 47 subjects (41.6%) reported 
comorbidities, with the most common being diabetes 
mellitus (n = 30; 26.5%). Other reported comorbidities 
included: kidney diseases (n = 8; 7.1%), congestive 
heart failure (n = 6; 5.3%), cerebrovascular disease, and 
cancer (n = 5; 4.4% each). Concomitant disorders such 
as chronic obstructive pulmonary disease, history of 
gastric ulcers, liver disease, myocardial infarction, and 
peripheral vascular disease were reported in single 
subjects. 
As far as prior therapy is concerned, 74 (65.5%) 
individuals underwent at least one pituitary surgery 
(53 patients with one surgery, 20 patients with two 
surgeries, and one patient with three surgeries). During 
the enrolment visit, 11 (9.7%) patients reported hav-
ing been previously treated with dopamine agonists 
(bromocriptine or cabergoline) in addition to other 
SSAs. During the study 19 patients took one or more 
pituitary directed medication other than lanreotide 
Autogel; these included: dopamine agonists (n = 19; 
16.8%), and temozolomide (n = 1; 0.9%). 
All subjects were treated with a deep subcutaneous 
injection of lanreotide Autogel 120 mg in the conditions 
of everyday clinical practice. In almost 70% of cases, at 
each visit, a nurse in an outpatient clinic administered 
the drug. A minority of patients received lanreotide 
Autogel in hospital (17.1% at V1 and 15.7% at V3) 
or at home (13.5% at V1 and 15.7% at V3). Of these 
home-administrations, approximately 10% of patients 
self-administered and 4% were administered the drug 
by their partners.
The most common reason for a change in therapy 
from octreotide to lanreotide was unsatisfactory self-
reported efficacy of the original treatment (n = 50; 
44.2%). Approximately one-third of patients (n = 38; 
33.6%) changed treatments because of the high cost 
of octreotide therapy resulting from the government 
reimbursement policy in this period. Thirty-one (27.4%) 
patients changed therapies based on their personal 
choice. Table II summarises the reasons patients decided 
to switch therapies. 
A total of 53 (46.9%) patients were treated first with 
lanreotide Autogel delivered as pre-filled syringe (old 
device) followed by lanreotide Autogel as new device. 
The remainder (n = 60; 53.1%) only received lanreotide 
Autogel in the new delivery device. 
Assessment of overall satisfaction with treatment 
At the end of the study, 97 (95.1%) participants were 
either “completely satisfied” or “rather satisfied” with 
the lanreotide Autogel treatment, four (3.9%) were 
“neither satisfied nor dissatisfied”, and just one patient 
was “rather dissatisfied”. None of the patients who 
completed the study were “completely dissatisfied”. 
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Overall, 97 (95.1%) patients stated that they would like 
to continue with the lanreotide Autogel treatment after 
the completion of the study, with the remainder (n = 5; 
 4.9%) wishing not to continue.
Assessment of effectiveness  
of treatment with SSA 
At baseline, 54% of subjects assessed the effectiveness of 
previous SSAs in terms of control of acromegaly symp-
toms as either “excellent” or “good”. At the completion 
of the current study, 88–89% of subjects assessed the 
effectiveness of lanreotide Autogel as either “excellent” 
or “good” (Table III).
Assessment of technical problems relating to SSA 
administration
Figure 2 summarises the VAS scores related to technical 
problems of prior SSA administration in comparison 
to lanreotide Autogel. The mean (SD) VAS score for 
octreotide was 37.6 (26.5), and ranged from 0 to 88. 
Data for VAS scores relating to technical problems of 
administration of lanreotide Autogel were collected 
at each visit. A mean (SD) VAS score of 7.4 (11.7) was 
recorded at the enrolment visit; however, this decreased 
to a mean (SD) of 5.3 (8.5) at the last visit (V3).
Figure 1. Patient flow during the study
Rycina 1. Przepływ pacjentów podczas badania
Table I. Patient demographic and clinical characteristics at 
baseline 
Tabela I. Demograficzne i kliniczne cechy chorych na początku 
badania
Age [years; mean (SD)] 53.7 (12.9)
Height [cm; mean (SD)] 170.1 (9.6)
Weight [kg; mean (SD)] 86.3 (18.0)
Female [n (%)] 67 (59.3)
Time since acromegaly diagnosis [years; mean (SD)] 7.9 (7.92)
Previous pituitary surgery [n (%)] 74 (65.5)
Pituitary surgeries [n; mean (SD)] 1.3 (0.5)
Time since last pituitary surgery [years; mean (SD)] 7.9 (6.92)
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Assessment of treatment with lanreotide Autogel 
using the new device
The subgroup of 53 subjects received the first lanreotide 
Autogel injections with an old device and with a new 
device afterwards. Thirty-one patients assessed the new 
lanreotide Autogel device, and 20 (64.5%) declared that 
the ease of usage had been improved. Most participants 
appreciated the user-friendly handling (n = 15) and 
simple manual (n = 12). For 11 patients there was no 
difference between the old and new devices. None of 
the study participants assessed usage of the new device 
as worse than the old device. Fifty investigators also 
assessed the usage of the new device, and 46 (92.0%) 
reported that the usage of the new syringe, compared 
to the previous pre-filled syringe, had been improved. 
Importantly, investigators appreciated the user-friendly 
handling of the new lanreotide Autogel device.
Discussion 
In the current study, we showed that the majority of 
patients treated for a mean of 15 months with lanreo-
tide Autogel 120 mg were satisfied with the treatment, 
found it to be effective in controlling acromegaly-spe-
cific symptoms, and did not report technical problems 
relating to drug administration. In addition, patients 
reported the new lanreotide Autogel injection device 
to be an improvement in comparison to the previous 
method. These results indicate that the degree of patient 
satisfaction may represent patient preference in terms of 
treatment. In light of current results, given that the ma-
jority of patients reported satisfaction with lanreotide 
Autogel therapy, patient preference for this treatment 
may also be implied. These findings are consistent with 
the results of the international LEAD study, where, for 
all dosing interval groups tested, at least three-quarters 
of patients (eight-week extended dosing interval: 92.3%; 
six-week extended dosing interval: 77.9%; four-week 
dosing interval: 76.9%) preferred the lanreotide Autogel 
treatment to octreotide at the final phase of the study 
[11]. In the LEAD report, 120 mg of lanreotide Autogel 
was shown to be well tolerated, with adverse effects 
reported to be only mild or moderate in severity. Accord-
ing to the patient-assessed acromegaly questionnaire 
(PASQ) used at baseline, during and at the end of the 
LEAD study, treatment had little effect on the perceived 
acromegaly symptoms. In the PASQ, five symptoms and 
signs were assessed: headache, excessive perspiration, 
fatigue, soft tissue swelling, and arthralgia [18].
In 2012, the administration of lanreotide was made 
markedly easier thanks to the introduction of a new 
syringe (injection device). This method of delivery re-
duces the risk of errors in reconstitution, and improves 
the predictability and reliability of accurate dose adjust-
ment. Our findings of preference for the new lanreotide 
injection device also reflect those of another study, 
which interviewed nurses who administered SSAs. 
The study found nurses to have a greater appreciation 
for the ease and convenient preparation and injection 
method offered by the novel device. It also found it to 
offer a shorter mean preparation and administration 
time than the octreotide long-acting release device. 
Overall, the study showed the nurses to prefer the new 
Table III. Effectiveness of SSAs on acromegaly symptom control 
Tabela III. Skuteczność SSA w kontroli objawów akromegalii
Octreotide Lanreotide Autogel
N = 113 
n (%)
V0 
N = 113 
n (%)
V1 
N = 111 
n (%)
V2 
N = 107 
n (%)
V3 
N = 102 
n (%)
Excellent 9 (8.0) 33 (29.2) 35 (31.5) 34 (31.8) 44 (43.1)
Good 52 (46.0) 66 (58.4) 63 (56.8) 60 (56.1) 47 (46.1)
Acceptable 39 (34.5) 11 (9.7) 9 (8.1) 10 (9.3) 9 (8.8)
Poor 11 (9.7) 2 (1.8) 3 (2.7) 3 (2.8) 2 (2.0)
Very poor 2 (1.8) 1 (0.9) 1 (0.9) 0 0
Missing 0 0 2 0 0
Table II. Reasons for change of treatment from octreotide to 
lanreotide Autogel 
Tabela II. Przyczyny zmiany leczenia oktreotydem na 
lanreotyd Autogel
Reason n (%)
Unsatisfactory efficacy 50 (44.2)
Cost of treatment 38 (33.6)
Patient’s decision 31 (27.4)
Injection site reactions 18 (15.9)
Unsatisfactory safety 6 (5.3)
Other reasons 24 (21.2)
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lanreotide-administering device, not only for reasons of 
ease, convenience, and speed, but also for the reduced 
risk of clogging and improved dosage confidence [19]. 
From the patients’ point of view, greater assurance of 
correct drug dosage upon administration may reduce 
the stress associated with receiving treatment, and may 
relieve concerns that the therapy could be unsuccess-
ful due to incorrect dosing. Unsatisfactory efficacy was 
the most common reason patients decided to change 
medication, from octreotide to lanreotide, before being 
enrolled in our study. The development of the new 
syringe, which is both enhanced and easier to use than 
previous injection devices, may encourage patients to 
self-administer the drug; additionally, the convenience 
it offers may be attractive to subjects who wish to save 
time (by eliminating a trip to the doctor) or for those who 
live great distances from medical centres. Despite the 
ease of the novel device, many patients still choose not 
to self-administer. In our study, the drug was primarily 
administered by a nurse in an outpatient clinic. Future 
research should focus on this issue, because the reasons 
underlying patient unwillingness to self-administer is 
key to improving treatment outcomes in the long-term.
Nowadays, the doctor — patient relationship in-
clines more toward a balanced partnership and shared 
decision making: physicians are expected to consider 
patients’ preferences and their influence on adherence 
to therapy [12, 20]. The authors of the aforementioned 
LEAD study reasoned that patient preference might 
correlate with improved adherence to treatment. Al-
though our study did not assess adherence, research 
in other fields has clearly shown a notable relationship 
between patient adherence and success of treatment 
[21]. This is of considerable importance given the 
chronic nature of acromegaly: it is a disease associated 
with significant comorbidities, and demands long-term 
treatment, typically with SSAs. When considering dis-
ease management and treatment plans, it is therefore 
critical to consider, both the potential success of the 
treatment (relative to the likelihood of adherence) and 
patient QoL. As stated by Adelman et al., it is impor-
tant to consider the impact of the treatment on the 
patient’s QoL, just as much as the disease. Despite this 
understanding, improving patient QoL can be difficult 
[22], and discordant results have been reported in the 
literature. For example, in the LEAD study, the results 
of the AcroQoL questionnaire showed that patients 
perceived the change of treatment to have no effect 
on their QoL. On the other hand, recently published 
data from the PRIMARYS study demonstrated that 48 
weeks of treatment with lanreotide Autogel resulted in 
an improvement in both subjective perception of signs 
and symptoms as measured by the PASQ and QoL 
as assessed by the AcroQoL [23]. Treatment naivety 
could be one of explanations of such discrepancies: 
patients in the LEAD study were previously treated 
with octreotide, and patients in the PRIMARYS study 
were treatment naïve. Furthermore, the latter patients 
were homogenous with regard to the type of pituitary 
tumour, since all had macroadenoma with diameter 
≥ 10 mm. We observed in our study that the change 
from octreotide to lanreotide Autogel significantly in-
creased patient satisfaction. Although this raises issues 
related to perceived and actual benefit, it does highlight 
that patient preference, likelihood of adherence to treat-
ment, and success of treatment should be considered 
during acromegaly management. 
Our study population encompassed approximately 
20% of all patients treated with SSAs in Poland; how-
ever, we acknowledge that the main limitation of our 
study is the generalisation of the findings. We consid-
ered whether our patients were representative, in the 
context of previously published studies, and found 
demographic characteristics from another multicentre 
Polish Lanro-Study to be similar to our own. Specifi-
cally, the mean ages were 51.7 years (Lanro-Study) vs. 
53.7 years (this study), and the percentage of women 70.5% 
(Lanro-Study) vs. 59.3% (this study). We also found the 
treatment history of these two groups to be similar: 
75% underwent pituitary surgery in the Lanro-Study 
vs. 74% in the current study. In addition, the mean time 
since last pituitary surgery was also similar: 7.7 years 
(Lanro-Study) vs. 7.9 years (this study) [24]. Although 
Figure 2. Technical problems related to prior SSA and lanreotide 
Autogel administration (data shown as mean, SD). VAS — Visual 
Analog Scale; SSA — somatostatin analog; V0, V1, V2, V3 — 
visit 0, 1, 2, 3
Rycina 2. Problemy techniczne związane z aplikowaniem 
wcześniejszego SSA i lanreotydu Autogel (dane przedstawione jako 
średnia, SD). VAS — wizualna skala analogowa; SSA — analog 
somatostatyny; V0, V1, V2, V3 — wizyty: 0,1, 2, 3
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this is a single comparison, we assume our results 
can be extrapolated to accurately represent the Polish 
population who currently suffer from acromegaly. An 
additional limitation of our study is its observational 
nature with retrospective control data. 
Conclusions
Therapy with lanreotide Autogel is related to higher 
levels of patient satisfaction with acromegaly manage-
ment, when compared to a previously used SSA (in 
this case, octreotide). We conclude that this, in turn, 
may translate to patient treatment preferences. This 
preference is important for physician consideration 
when administering a novel treatment and the likeli-
hood of patient adherence. Our findings indicate that 
the control of acromegaly-specific symptoms was 
improved as a result of treatment with the new lan-
reotide device, and this tool addresses certain technical 
problems associated with SSA injections. Despite the 
positive effects of the treatment, we did not observe 
any direct influence on rates of self-administration of 
lanreotide. Uncovering the underlying reasons pre-
venting patients from self-administering is the key to 
further improvement of QoL in these patients in the 
longer term.
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